Eli Lilly forecasts it will make between $58 billion and $61 billion in revenue this year|Momoneymoproblemz|CC BY-SA 4.0

American pharma giant Eli Lilly’s profits soared in the fourth quarter, fueled by the sales of its GLP-1 drugs Mounjaro and Zepbound. Revenue jumped 45% to $13.53 billion, and profits doubled to $4.41 billion.

In the last quarter of 2024, diabetes treatment Mounjaro pulled in $3.53 billion (up 60%), while anti-obesity drug Zepbound contributed $1.9 billion. Breast cancer drug Verzenio also boosted earnings, rising 36% to $1.55 billion.

GLP-1 drugs from Lilly and competitor Novo Nordisk have risen in popularity for the last two years due to the weight loss recipients experienced while taking the injections.

For 2025, analysts expect over $18 billion in Mounjaro sales and more than $10 billion from Zepbound buys.

Lilly forecasts it will make between $58 billion and $61 billion in revenue this year. Investors took notice, and its shares jumped 2% Thursday morning, which is already up 9% this year.